NCT05745285 Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
| NCT ID | NCT05745285 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Miami |
| Condition | Leukemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2025-02-04 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2025-02-04 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to learn about the impact that the services and programs provided by Blood Cancer United (formerly, The Leukemia and Lymphoma Society) have among patients with blood cancer, such as access to care, quality of life, and financial burden.
Eligibility Criteria
Inclusion Criteria: * Be diagnosed with, or have a recurrence of leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN). * Have received, be receiving, or be planning to receive primary or relapse treatment for leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN) and meet at least one of the following criteria: * Be currently receiving treatment which started within the past 18 months OR * Be planning to start treatment within one month OR * Have received Bone Marrow Transplant or CAR-T cell therapy within the past 100 days. * Not be currently participating in any LLS programs or services * Be willing to be followed for 6 months * Speak English or Spanish Exclusion Criteria: * Are not diagnosed with, or have a recurrence of leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN) * Do not meet at least one of the following criteria if treated or planning to get treated for leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN): * Be currently receiving treatment which started within the past 18 months OR * Be planning to start treatment within one month OR * Have received Bone Marrow Transplant or CAR-T cell therapy within the past 100 days. * Are currently participating in any LLS programs or services * Are not willing to be followed for 6 months * Do not speak English or Spanish.
Contact & Investigator
Frank Penedo, PhD
PRINCIPAL INVESTIGATOR
University of Miami
Frequently Asked Questions
Who can join the NCT05745285 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05745285 currently recruiting?
Yes, NCT05745285 is actively recruiting participants. Contact the research team at cam32407@med.miami.edu for enrollment information.
Where is the NCT05745285 trial being conducted?
This trial is being conducted at Miami, United States, Chicago, United States, San Antonio, United States.
Who is sponsoring the NCT05745285 clinical trial?
NCT05745285 is sponsored by University of Miami. The principal investigator is Frank Penedo, PhD at University of Miami. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.